Cargando…
Comparison of best supportive care, CHOP, or R-CHOP for treatment of diffuse large B-cell lymphoma in Malawi: a cost-effectiveness analysis
BACKGROUND: Cost-effectiveness data for cancer treatment are needed from sub-Saharan Africa, where diffuse large B-cell lymphoma (DLBCL) is a common, curable cancer. In high-income countries, the standard of care for DLBCL is R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednis...
Autores principales: | Painschab, Matthew S, Kohler, Racquel, Kimani, Stephen, Mhango, Wilberforce, Kaimila, Bongani, Zuze, Takondwa, Mithi, Victor, Kasonkanji, Edwards, Mumba, Noel, Nyasosela, Richard, Wheeler, Stephanie, Gopal, Satish |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8403678/ https://www.ncbi.nlm.nih.gov/pubmed/34303416 http://dx.doi.org/10.1016/S2214-109X(21)00261-8 |
Ejemplares similares
-
Microcosting Analysis of Diffuse Large B-Cell Lymphoma Treatment in Malawi
por: Painschab, Matthew S., et al.
Publicado: (2019) -
Comparison of baseline lymphoma and HIV characteristics in Malawi before and after implementation of universal antiretroviral therapy
por: Gondwe, Yolanda, et al.
Publicado: (2022) -
Safety and efficacy of rituximab in patients with diffuse large B-cell lymphoma in Malawi: a prospective, single-arm, non-randomised phase 1/2 clinical trial
por: Kimani, Stephen, et al.
Publicado: (2021) -
Rosai‐Dorfman disease in Malawi
por: Kasonkanji, Edwards, et al.
Publicado: (2018) -
CHOP Chemotherapy for Aggressive Non-Hodgkin Lymphoma with and without HIV in the Antiretroviral Therapy Era in Malawi
por: Gopal, Satish, et al.
Publicado: (2016)